首页> 外文期刊>Acta orthopaedica. >Biological treatment of the knee with platelet-rich plasma or bone marrow aspirate concentrates
【24h】

Biological treatment of the knee with platelet-rich plasma or bone marrow aspirate concentrates

机译:富血小板血浆或骨髓抽吸浓缩物对膝关节的生物治疗

获取原文
           

摘要

— Knee pathologies including focal cartilage injuries, osteoarthritis (OA), and ligament injuries are common. The poor regeneration and healing potential of cartilage has led to the search for other treatment modalities with improved healing capacity. Furthermore, with an increasing elderly population that desires to remain active, the burden of knee pathologies is expected to increase. Increased sports participation and the desire to return to activities faster is also demanding more effective and minimally invasive treatment options. Thus, the use of biologic agents in the treatment of knee pathologies has emerged as a potential option. Despite the increasing use of biologic agents for knee pathology, there are conflicting results on the efficacy of these products. Furthermore, strong data supporting the optimal preparation methods and composition for widely used biologic agents, such as platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMAC), largely remain absent from the liter...
机译:—膝关节病理包括常见的软骨损伤,骨关节炎(OA)和韧带损伤。软骨再生和愈合潜力差,导致人们寻求其他具有改善愈合能力的治疗方式。此外,随着希望保持活跃的老年人口的增加,预计膝部疾病的负担会增加。运动参与度的提高和更快地恢复活动的愿望也要求更加有效和微创的治疗选择。因此,在膝盖疾病的治疗中使用生物制剂已成为一种潜在的选择。尽管越来越多地将生物制剂用于膝关节病理学,但这些产品的功效却存在矛盾的结果。此外,该文献中仍然缺少支持广泛使用的生物制剂(例如富血小板血浆(PRP)和骨髓抽吸浓缩液(BMAC))的最佳制备方法和成分的强大数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号